title: Overcoming the toxicity hurdles of genetically targeted T cells.
abstract: The recent successes of clinical trials with T cells genetically modified with either clonal T cell receptors or chimeric antigen receptors have also highlighted their potential toxicities. The aim of this focused review was to describe the adverse events observed in these clinical trials and to link them to the complex biology of genetically targeted T cells. Finally, strategies to overcome these toxicities will be proposed and discussed, including the use of suicide genes and other innovative gene therapy strategies.
authors.affiliation: Innovative Immunotherapies Unit, Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Hospital Scientific Institute, Via Olgettina 60, 20132, Milan, Italy.
authors.forename: Monica
authors.initials: M
authors.lastname: Casucci
authors.forename: Robert E
authors.initials: RE
authors.lastname: Hawkins
authors.forename: Gianpietro
authors.initials: G
authors.lastname: Dotti
authors.forename: Attilio
authors.initials: A
authors.lastname: Bondanza
mesh_terms: D000818:Animals; D064987:Cell- and Tissue-Based Therapy; D005818:Genetic Engineering; D006801:Humans; D016219:Immunotherapy, Adoptive; D009369:Neoplasms / Q000235:genetics / Q000276:immunology* / Q000628:therapy; D011946:Receptors, Antigen / Q000276:immunology*; D011948:Receptors, Antigen, T-Cell / Q000276:immunology*; D011993:Recombinant Fusion Proteins / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology* / Q000378:metabolism
chemical_list: D011946:Receptors, Antigen; D011948:Receptors, Antigen, T-Cell; D011993:Recombinant Fusion Proteins